Piperacillin Population Pharmacokinetics in Children Supported With Extracorporeal Membrane Oxygenation
Authors:
- Adrien ArsèneAAAdrien Arsène
- Mehdi OualhaMOMehdi Oualha
- Jérôme RambaudJRJérôme Rambaud
- Sihem BenaboudSBSihem Benaboud
- Saik UrienSUSaik Urien
- Marion GrimaudMGMarion Grimaud
- Sylvain RenolleauSRSylvain Renolleau
- Pierre-Louis LégerPLPierre-Louis Léger
- Déborah HirtDHDéborah Hirt
- Jean-Marc TréluyerJTJean-Marc Tréluyer
- Agathe BérangerABAgathe Béranger
- 6 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (9) , 1138-1147
Abstract
OBJECTIVE: To characterize piperacillin population pharmacokinetics (PK) in critically ill children with and without extracorporeal membrane oxygenation (ECMO) support and to optimize piperacillin dosing regimens to attain the PK target of 100% free time above minimum inhibitory concentration (fT > minimum inhibitory concentration). DESIGN: Post hoc secondary analysis of a two-center, population PK modeling and simulation study (registered at clinicaltrials.gov, NCT02539407). SETTINGS: PICUs at tertiary care centers, September 2015–November 2021. PATIENTS: Thirty-three children supported with ECMO and 50 non-ECMO control patients treated with piperacillin (± tazobactam). INTERVENTIONS: Administration of piperacillin at 300 mg/kg/d by continuous infusion or 75 mg/kg every 6 hours by intermittent infusion. MEASUREMENTS AND MAIN RESULTS: A one-compartment linear-elimination model described best the piperacillin data. Clearance was driven by body weight and estimated glomerular filtration rate (eGFR). In a typical 11-kg patient, ECMO circuit volume-to-weight ratio increased the volume of distribution by 34%. Monte Carlo simulations across eGFR strata (30–60, 60–90, 90–150, 150–200, 200–300 mL/min/1.73 m 2 ) showed that a continuous infusion of 300 mg/kg/d allowed greater than or equal to 90% of target attainment in all groups. Patients with an eGFR greater than 200 mL/min/1.73 m 2 required 400 mg/kg/d to have 90% of target attainment. CONCLUSIONS: Continuous infusion of 300 mg/kg/d piperacillin reliably achieves PK target across all renal‐function ranges in children undergoing support with ECMO. Dose escalation to 400 mg/kg/d is required for augmented renal clearance (eGFR > 200 mL/min/1.73 m 2 ).Keywords
This publication has 30 references indexed in Scilit:
- Antimicrobial pharmacokinetics and dosing in critically ill adults receiving prolonged intermittent renal replacement therapy: A systematic reviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal functionClinical Microbiology and Infection, 2022
- Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapyClinical Microbiology and Infection, 2022
- Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)International Journal of Antimicrobial Agents, 2021
- Population pharmacokinetics of meropenem in critically ill children with different renal functionsEuropean Journal of Clinical Pharmacology, 2019
- Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal ClearanceClinical Pharmacokinetics, 2018
- Clinical Pharmacology Studies in Critically Ill ChildrenPharmaceutical Research, 2016
- Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenationJournal of the Formosan Medical Association, 2016
- Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropeniaPediatric Blood & Cancer, 2014
- Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenationJournal of Critical Care, 2012